NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 115, Issue 47, Pages 12034-12039
Publisher
Proceedings of the National Academy of Sciences
Online
2018-11-08
DOI
10.1073/pnas.1806928115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
- (2018) Patrick Casara et al. Oncotarget
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
- (2017) Delphine Merino et al. Science Translational Medicine
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
- (2016) M. A. Anderson et al. BLOOD
- A BH3 Mimetic for Killing Cancer Cells
- (2016) Douglas R. Green CELL
- BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics
- (2016) R. S. Soderquist et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials
- (2015) David M. Hyman et al. DRUG DISCOVERY TODAY
- Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
- (2015) L Li et al. LEUKEMIA
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
- (2015) D C Phillips et al. Blood Cancer Journal
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
- (2012) R W Rooswinkel et al. Cell Death & Disease
- Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
- (2011) J. M. Tromp et al. CLINICAL CANCER RESEARCH
- Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
- (2011) K. M. Lucas et al. CLINICAL CANCER RESEARCH
- Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA
- (2010) Barbora Brodská et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
- (2009) S. Chen et al. MOLECULAR AND CELLULAR BIOLOGY
- Noxa: at the tip of the balance between life and death
- (2009) C Ploner et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started